Drug
Tak 279
Tak 279: highest development phase Phase 3, developed by Takeda. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| TAK-279 NCT06323356 | Phase 3 | Generalized Pustular Psoriasis |
| TAK-279 NCT06233461 | Phase 2 | Crohn's Disease |
| TAK-279 NCT06258265 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Tak 279 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.